Luis G. Paz-Ares, MD, PhD, on Small Cell Lung Cancer: Efficacy and Safety of Lurbinectedin
2019 ASCO Annual MeetingLuis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, discusses study findings on the second-line use of lurbinectedin in patients with both resistant and sensitive small cell lung cancer (Abstract 8506).
Related Videos
Francesca Gay, MD, on Multiple Myeloma: Carfilzomib/Lenalidomide/Dexamethasone With or Without Transplantation
Francesca Gay, MD, of GIMEMA, European Myeloma Network, discusses the results of the FORTE trial on the efficacy of carfilzomib/lenalidomide/dexamethasone with or without autologou...
Neeraj Agarwal, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: KEYNOTE-426 on First-Line Pembrolizumab Plus Axitinib vs Sunitinib
Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas Powles, MD, PhD, of Queen Mary University of London, discuss phase III...
Rowan T. Chlebowski, MD, PhD, on Breast Cancer Incidence and Mortality: Results From the Women’s Health Initiative on the Effects of a Low-Fat Diet
Rowan T. Chlebowski, MD, PhD, of the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, discusses study findings from nearly 2 decades of data, which sh...
Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy
Jason Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings of the Smart Start study on the chemotherapy-free combination of rituximab, lenalid...
Mark J. Levis, MD, PhD, on Acute Myeloid Leukemia: Gilteritinib in FLT3-Mutated Disease
Mark J. Levis, MD, PhD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, discusses the effect of gilteritinib on survival in patients with FL...
